Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors Academic Article uri icon

Overview

MeSH Major

  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids

abstract

  • Belinostat has modest antitumor activity in this group of heavily pretreated thymic malignancies. However, the duration of response and disease stabilization is intriguing, and additional testing of belinostat in this disease is warranted.

publication date

  • May 20, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3107761

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.32.4467

PubMed ID

  • 21502553

Additional Document Info

start page

  • 2052

end page

  • 9

volume

  • 29

number

  • 15